lactic acid has been researched along with Urinary Retention in 3 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Urinary Retention: Inability to empty the URINARY BLADDER with voiding (URINATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess whether patients in acute urinary retention from benign prostatic enlargement can be treated with a combined therapy comprising finasteride and a bioabsorbable self-reinforced poly L-lactic acid (SR-PLLA) urethral stent." | 9.09 | A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from ( Hellström, P; Isotalo, T; Perttilä, I; Talja, M; Tammela, TL; Törmälä, P; Välimaa, T, 2001) |
| "To evaluate, in a pilot study, the efficacy and safety of combining a braided poly(lactic-co-glycolic acid) (PLGA, a copolymer of l-lactide and glycolide) urethral stent and dutasteride in the treatment of acute urinary retention (AUR) due to benign prostatic enlargement (BPE)." | 7.75 | Biodegradable braided poly(lactic-co-glycolic acid) urethral stent combined with dutasteride in the treatment of acute urinary retention due to benign prostatic enlargement: a pilot study. ( Hänninen, V; Isotalo, T; Juuti, H; Kellomäki, M; Kotsar, A; Leppiniemi, J; Mikkonen, J; Talja, M; Tammela, TL, 2009) |
| "To assess whether patients with acute urinary retention from benign prostatic enlargement can be treated with a combined therapy comprising a bioabsorbable self-reinforced poly L-lactic acid (SR-PLLA) urethral stent and finasteride." | 7.70 | A pilot study of a bioabsorbable self-reinforced poly L-lactic acid urethral stent combined with finasteride in the treatment of acute urinary retention from benign prostatic enlargement. ( Isotalo, T; Talja, M; Tammela, TL; Törmälä, P; Välimaa, T, 2000) |
| "To assess whether patients in acute urinary retention from benign prostatic enlargement can be treated with a combined therapy comprising finasteride and a bioabsorbable self-reinforced poly L-lactic acid (SR-PLLA) urethral stent." | 5.09 | A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from ( Hellström, P; Isotalo, T; Perttilä, I; Talja, M; Tammela, TL; Törmälä, P; Välimaa, T, 2001) |
| "To evaluate, in a pilot study, the efficacy and safety of combining a braided poly(lactic-co-glycolic acid) (PLGA, a copolymer of l-lactide and glycolide) urethral stent and dutasteride in the treatment of acute urinary retention (AUR) due to benign prostatic enlargement (BPE)." | 3.75 | Biodegradable braided poly(lactic-co-glycolic acid) urethral stent combined with dutasteride in the treatment of acute urinary retention due to benign prostatic enlargement: a pilot study. ( Hänninen, V; Isotalo, T; Juuti, H; Kellomäki, M; Kotsar, A; Leppiniemi, J; Mikkonen, J; Talja, M; Tammela, TL, 2009) |
| "To assess whether patients with acute urinary retention from benign prostatic enlargement can be treated with a combined therapy comprising a bioabsorbable self-reinforced poly L-lactic acid (SR-PLLA) urethral stent and finasteride." | 3.70 | A pilot study of a bioabsorbable self-reinforced poly L-lactic acid urethral stent combined with finasteride in the treatment of acute urinary retention from benign prostatic enlargement. ( Isotalo, T; Talja, M; Tammela, TL; Törmälä, P; Välimaa, T, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kotsar, A | 1 |
| Isotalo, T | 3 |
| Juuti, H | 1 |
| Mikkonen, J | 1 |
| Leppiniemi, J | 1 |
| Hänninen, V | 1 |
| Kellomäki, M | 1 |
| Talja, M | 3 |
| Tammela, TL | 3 |
| Välimaa, T | 2 |
| Törmälä, P | 2 |
| Hellström, P | 1 |
| Perttilä, I | 1 |
1 trial available for lactic acid and Urinary Retention
| Article | Year |
|---|---|
A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from
Topics: Absorbable Implants; Aged; Aged, 80 and over; Combined Modality Therapy; Double-Blind Method; Enzyme | 2001 |
2 other studies available for lactic acid and Urinary Retention
| Article | Year |
|---|---|
Biodegradable braided poly(lactic-co-glycolic acid) urethral stent combined with dutasteride in the treatment of acute urinary retention due to benign prostatic enlargement: a pilot study.
Topics: Acute Disease; Aged; Aged, 80 and over; Azasteroids; Biocompatible Materials; Dutasteride; Enzyme In | 2009 |
A pilot study of a bioabsorbable self-reinforced poly L-lactic acid urethral stent combined with finasteride in the treatment of acute urinary retention from benign prostatic enlargement.
Topics: Acute Disease; Aged; Aged, 80 and over; Ambulatory Care; Combined Modality Therapy; Enzyme Inhibitor | 2000 |